TABLE 2

Outcome measures by treatment arm

CPEErlotinib monotherapyHR (95% CI)
Patients randomised1111
PFS months, median (95% CI)13.7 (5.2–18.8)10.3 (7.1–15.5)0.62 (0.25–1.57)#
Overall survival, median (95% CI)31.7 (21.8–61.9)17.2 (11.5–45.5)0.55 (0.22–1.41)
1-year overall survival, % (95% CI)100 (72–100)
ORR, % (95% CI)64 (31–89)55 (23–83)
 Complete response1 (9)1 (9)
 Partial response6 (54)5 (46)
 Stable disease4 (36)5 (46)
Duration of response in months, median (95% CI)10.8 (7.3–31.2)8.0 (5.5–8.7)0.43 (0.12–1.47)

Data are presented as n or n (%), unless otherwise stated. CPE: cisplatin-pemetrexed-erlotinib; HR: hazard ratio; PFS: progression-free survival; ORR: overall response rate. #: after compensating for numbers of days receiving erlotinib HR 0.24, 95% CI 0.07–0.83; p=0.02.